Berman Howard 4

What Happened
Berman Howard, a director of Atea Pharmaceuticals, received two equity awards on June 18, 2026: 26,700 restricted stock units (RSUs) and 37,700 derivative awards (stock options), each reported at an acquisition price of $0. These are grants (not open-market purchases or sales) and do not represent immediate cash proceeds to the insider.

Key Details

• Transaction date: 2026-06-18; Form 4 filed 2026-06-23 (filed after the usual 2-business-day window).
• Award amounts and reported prices: 26,700 RSUs @ $0; 37,700 options (derivative) @ $0. Reported total acquisition value on the Form 4 = $0 (grant).
• Vesting: RSUs vest in a single installment on the earlier of the next annual meeting after 6/18/2026 or June 18, 2027, subject to continued service. The option vests in 12 substantially equal monthly installments following 6/18/2026, fully vesting on 6/18/2027, subject to continued service.
• Shares owned after the transaction: not provided in the supplied summary of the Form 4.
• Footnotes: F1 describes RSUs (each converts to one share on vesting). F2/F3 detail the vesting schedules above.
• Filing timeliness: The Form 4 appears to have been filed late relative to the typical 2-business-day filing requirement (filed 5 calendar days / 3 business days after the transaction).

Context
These were grants of equity compensation (awards), which are routine for directors and reflect future potential equity rather than an immediate purchase or sale. RSUs convert to shares on vesting; the options must be exercised after vesting to obtain shares. Because this is a grant reported at $0, it does not indicate cash invested by the insider and should not be interpreted as a buy or sell signal by itself.